1. Established in December 1993, Medicamen Group has vertically integrated facilities in terms of R&D, APIs & Formulations.
2. The company is now focusing on oncology therapeutics & other generics with a vision to be a Global Leader in Oncology generics by offering affordable medicine with best-in-class quality.
3. Apart from the above, a set of 10 Non-oncology formulations is also being determined in R & D for EU market filings.
4. The company has firm plans & investments for Global rollout of its oncology Products in USA, Europe, Latin America, Asia-Pacific, MENA etc. through a combination of own team & alliance partners.
Infrastructure Highlights :-
1. R&D Centre approved by Department of Scientific & Industrial Research(DSIR), at Bhiwadi, (Rajasthan, India) for carrying out Chemical, Analytical and Formulation R&D.
2. A state-of-the-art API manufacturing facility under its parent company, Shivalik Rasayan Limited, at Dahej (Gujarat, India) conforming to requirements of highly regulated markets having separate blocks for oncology and other generics.
3. Three manufacturing facilities for Finished Dosage Forms (FDF):
4. First Formulation (FDF) facility established in 1993 for General Formulations at Bhiwadi (Rajasthan, India). This plant has been audited by an EU member country and is soon expected to be an EU-approved facility.
5. Second Formulation(FDF) facility established in 2007 for General Formulations at Haridwar Unit-I (Uttarakhand, India)
6. Third FDF facility established in 2021 for Oncology Injectables (Lyo & RTU) and Oral Solid Dosage Forms at Haridwar Unit-II (Uttarakhand, India). This plant is approvable by leading global regulatory agencies such as USFDA, EDQM, PMDA, TGA etc.